Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
TE TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD FY ended Dec 31, 2025 | $36.44 | $42.46B | $63.85B | $17.26B | $3.15B | $1.41B | 30.12x | 2.46x | 15.58x |
BH BHC Bausch Health Companies Inc. FY ended Feb 13, 2026 | $6.32 | $2.36B | $19.36B | $10.27B | $4.32B | $157.00M | 15.05x | 0.23x | 4.46x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
AN ANIP ANI PHARMACEUTICALS INC FY ended Dec 31, 2025 | $72.83 | $1.64B | $2.20B | $883.37M | $187.66M | $78.34M | 21.94x | 1.85x | 10.07x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 9.95x | 4/5 | $1.76B | $41.30 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 1.57x | 5/5 | $1.13B | $26.53 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 16.99x | 5/5 | $1.67B | $39.17 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
TE TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD FY ended Dec 31, 2025 | $36.44 | $42.46B | $63.85B | $17.26B | $3.15B | $1.41B | 30.12x | 2.46x | 15.58x |
BH BHC Bausch Health Companies Inc. FY ended Feb 13, 2026 | $6.32 | $2.36B | $19.36B | $10.27B | $4.32B | $157.00M | 15.05x | 0.23x | 4.46x |
PR PRGO PERRIGO Co plc FY ended Feb 24, 2026 | $14.48 | $2.01B | $4.70B | $4.25B | -$781.50M | -$1.43B | -1.41x | 0.47x | — |
AN ANIP ANI PHARMACEUTICALS INC FY ended Dec 31, 2025 | $72.83 | $1.64B | $2.20B | $883.37M | $187.66M | $78.34M | 21.94x | 1.85x | 10.07x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 9.95x | 4/5 | $1.76B | $41.30 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 1.57x | 5/5 | $1.13B | $26.53 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 16.99x | 5/5 | $1.67B | $39.17 | Included in the active peer mix. |
